How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella?. Issue 34 (7th August 2019)

• Record Type: Journal Article
• Authors: Giersing, Birgitte K.; Porter, Chad K.; Kotloff, Karen; Neels, Pieter; Cravioto, Alejandro; MacLennan, Calman A.
• Is Part Of: Vaccine. Volume 37:Issue 34(2019)
• Page Start: 4778
• Page End: 4783
• Publication Date: 2019-08-07
• Subjects: Shigella -- Challenge -- Vaccine -- Development -- Policy; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2019.03.036
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Controlled Human Infection Models (CHIMs) now exist for several infectious diseases. CHIMs offer significant insight into disease pathogenesis, as well the potential to rapidly test clinical proof-of-concept of vaccine candidates. The application of CHIMs to identify a correlate of protection that may reduce the sample size of, or obviate the need for clinical efficacy studies to achieve licensure is of considerable interest to vaccine developers and public health stakeholders. This topic was the subject of a workshop at the 2018 Vaccines Against Shigella and ETEC (VASE) conference, in the context of O-antigen-based Shigella vaccines.